Fact or fiction: What do the benign prostatic hyperplasia data tell us?

被引:3
|
作者
Shabbir M. [1 ]
Kirby R.S. [1 ]
机构
[1] The London Clinic, 20 Devonshire, London
关键词
Benign Prostatic Hyperplasia; Finasteride; International Prostate Symptom Score; Lower Urinary Tract Symptom; Tamsulosin;
D O I
10.1007/s11934-005-0016-3
中图分类号
学科分类号
摘要
Benign prostatic hyperplasia (BPH) is the most common benign neoplasm in men. Our understanding of this condition has improved greatly over the years and recent advances have changed our approach to management. At the end of the 19th century, prostatic enlargement was treated effectively by bilateral orchidectomy. Unsurprisingly, this treatment option never gained widespread popularity. Less than 10 years ago, surgery and watchful waiting were the only considered treatment options for BPH. We now have a number of medical therapies and minimally invasive treatment options available that can effectively manage lower urinary tract symptoms secondary to benign prostatic obstruction. However, with increased choice comes the increased need for clarity in selection and application of these various treatment options. In the current environment of evidence-based clinical practice, awareness and interpretation of data from the numerous studies is paramount. The lessons learned from these trials should be reflected clearly in our practice, with clinical management based on fact, not fiction. In this review, we critically assess the available data and understanding of the management of BPH. © 2005, Current Science Inc.
引用
收藏
页码:243 / 250
页数:7
相关论文
共 50 条
  • [1] What Do I Tell Patients About Saw Palmetto for Benign Prostatic Hyperplasia?
    Kane, Christopher J.
    Raheem, Omer A.
    Bent, Stephen
    Avins, Andrew L.
    [J]. UROLOGIC CLINICS OF NORTH AMERICA, 2011, 38 (03) : 261 - +
  • [2] Benign prostatic hyperplasia - what do we know?
    Devlin, Conor M.
    Simms, Matthew S.
    Maitland, Norman J.
    [J]. BJU INTERNATIONAL, 2021, 127 (04) : 389 - 399
  • [3] Social care data in England: What they tell us and what they do not tell us
    Kemm, J. R.
    Robinson, J.
    Verne, J.
    [J]. PUBLIC HEALTH, 2010, 124 (05) : 265 - 268
  • [4] What do we know about phytotherapy of benign prostatic hyperplasia?
    Allkanjari, Olta
    Vitalone, Annabella
    [J]. LIFE SCIENCES, 2015, 126 : 42 - 56
  • [5] Hip Resurfacing Data from National Joint Registries What Do They Tell Us? What Do They Not Tell Us?
    Corten, Kristoff
    MacDonald, Steven J.
    [J]. CLINICAL ORTHOPAEDICS AND RELATED RESEARCH, 2010, 468 (02) : 351 - 357
  • [6] The data speak but what do they tell us? Introduction
    [J]. OCCUPATIONAL INJURY: RISK, PREVENTION AND INTERVENTION, 1998, : 1 - 3
  • [7] Chronic Inflammatory Infiltrate and Benign Prostatic Hyperplasia: What Do We Know?
    Bartoletti, Riccardo
    [J]. EUROPEAN UROLOGY SUPPLEMENTS, 2013, 12 (05) : 99 - 102
  • [8] What expectations do men with benign prostatic hyperplasia (BPH) have for treatment?
    Kotak, S
    Barron, R
    [J]. VALUE IN HEALTH, 2006, 9 (03) : A55 - A55
  • [9] Metabolic Syndrome and Benign Prostatic Hyperplasia/What Component of Metabolic Syndrome Is Related to Benign Prostatic Hyperplasia?
    Tarim, Bahar Arican
    Camur, Emre
    Kavukoglu, Ovunc
    Kosemen, Mete
    Ozgur, Yasemin
    Narter, Kamil Fehmi
    [J]. JOURNAL OF UROLOGICAL SURGERY, 2023, 10 (03): : 194 - 198
  • [10] Imaging in benign prostatic hyperplasia: what is new?
    Abdi, Hamidreza
    Kazzazi, Amir
    Bazargani, Soroush T.
    Djavan, Bob
    Telegrafi, Shpetim
    [J]. CURRENT OPINION IN UROLOGY, 2013, 23 (01) : 11 - 16